PT-141
FDA ApprovedStrong EvidenceBremelanotide
An FDA-approved melanocortin receptor agonist for female sexual dysfunction, and studied in men for erectile and libido enhancement.
Half-Life
~2.7 hours
Molecular Weight
1025.2 g/mol
PT-141 (bremelanotide) is a cyclic heptapeptide derived from the hormone alpha-MSH (alpha-melanocyte-stimulating hormone). Unlike most sexual function drugs that act on the vascular system (e.g. PDE5 inhibitors), PT-141 acts centrally through melanocortin receptors in the hypothalamus — directly modulating sexual motivation and arousal at the neurological level. It was FDA-approved in 2019 as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD). Research in men suggests benefits for erectile dysfunction, particularly in cases where PDE5 inhibitors are insufficient.
Also Known As
Amino Acid Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Reconstitution
Available as pre-filled autoinjector (Vyleesi). Research peptide requires reconstitution with bacteriostatic water; typical concentration 1 mg/mL.
Open Reconstitution Calculator →